The hepatic stellate cell (HSC) is now well established as the key cellular element involved in the development of hepatic fibrosis and because of this there is considerable interest in establishing the molecular events that trigger and perpetuate HSC activation. HSC activation at the level of gene transcription requires the coordinated activity of several key transcriptional regulators of the HSC genome. The considerable advances that have been made in the past five years into the mechanisms by which specific families of transcription factors regulate the profibrogenic characteristics of the activated HSC are reviewed. T he hepatic stellate cell (HSC) is now well established as the key cellular element involved in the development of hepatic fibrosis. In response to viral, chemical, or immune insult of the liver, the normally quiescent vitamin A storing HSC undergoes a dramatic phenotypic transformation termed "activation" or "transdifferentiation". 1 2 The process of HSC activation generates an α smooth muscle actin (α-SMA) positive myofibroblast-like cell that is proliferative and is responsible for deposition of the majority of excess extracellular matrix (ECM, predominantly types I and III collagen) that forms scar tissue in the fibrotic liver. [1] [2] [3] Because of its importance in the fibrotic process, there is considerable interest in establishing the molecular events that trigger and perpetuate HSC activation.
HSC activation is a highly pleiotropic process that involves gross morphological, behavioural, and biochemical changes. 1 These dramatic phenotypic changes require global reprogramming of HSC gene expression which in turn must be orchestrated by long term changes in the expression and/or activity of key transcriptional regulators of the HSC genome. Gene transcription in mammalian cells is controlled by the interaction of transcription factors with specific DNA sequences located in the regulatory regions of genes known as promoter or enhancer motifs. 4 Binding of transcription factors at these sites brings them into proximity with RNA polymerase II and its associated components of the basic transcription complex that assemble in the 5′ untranscribed region of a gene (fig 1) . The transcription factors are then able to exert either a positive or negative influence on the rate at which the basic transcription complex transcribes a gene. Because of the ability of transcription factors to exert a powerful regulatory role on the phenotype of cells, it is essential that their activity is also exquisitely controlled. The activity of a transcription factor is controlled at multiple levels. Because transcription factors are proteins, modulation of their expression and the more rapid attenuation of function via post-translational modification (phosphorylation, acetylation, ubiquitination, and interaction with coactivators and inhibitors) exert the greatest regulatory influence. [5] [6] [7] As these regulatory events are wired into a complex network of intracellular signal transduction pathways that are activated in response to cellular stimuli, they provide a finely tuned mechanism for altering transcription factor activity and subsequently the cellular phenotype according to the local requirements of a particular tissue. In the case of the injured liver the requirement is for production of the wound healing activated HSC. Perpetuation of this response in chronic liver disease results in the pathogenic state of fibrosis.
This article reviews the considerable advances that have been made in the past five years of research into the mechanisms by which specific families of transcription factors regulate the profibrogenic characteristics of the activated HSC.
NFκB
Nuclear factor κB (NFκB) is composed of heteroor homodimers of the Rel protein family (p65, p50, p52, c-Rel, and RelB), with the p65:p50 heterodimer being the classic NFκB complex induced by cytokine, mitogen, or UV stimulation of mammalian cells. 8 9 The level of cellular NFκB activity is determined by the properties of its naturally occurring inhibitors, of which inhibitor of NFκB (IκB-α) is the best characterised. [8] [9] [10] IκB-α regulates NFκB activity by directly interacting with the transcription factor to form inactive complexes that are localised to the cytoplasm. Stimulation of cells leads to activation of a cascade of signal transduction events that culminate in proteasome mediated degradation of IκB-α and the release of active NfκB. 10 NFκB dimers are then transported to the nucleus where they stimulate Abbreviations: HSC, hepatic stellate cells; α-SMA, α smooth muscle actin; ECM, extracellular matrix; NFκB, nuclear factor κB; IL-6, interleukin 6; ICAM-1, intercellular adhesion molecule 1; TNF-α, tumour necrosis factor α; TIMP-1, tissue inhibitor of metalloproteinase 1; MMP, matrix metalloproteinase; TGF, transforming growth factor; C/EBP, CCAAT/enhancer binding protein; bHLH, basic helix-loop-helix; M6P/IGFIIR, mannose 6-phosphate/ insulin-like growth factor II; PPARγ, peroxisome proliferator activated receptor γ; IκB-α, inhibitor of NFκB.
the transcription of genes that carry NFκB DNA binding motifs (GGGRNNYYCC, where R is purine, Y is pyrimidine, and N is any base), including the gene encoding IκB-α. 8 The ability of the IκB-α gene to enhance its rate of transcription in response to NFκB provides a negative feedback mechanism that within hours of the initial stimulatory event replenishes the cellular pool of the inhibitor and reverts NFκB back to its inactive state. [8] [9] [10] Several studies have shown that HSC activation is associated with elevation of NFκB activity.
11-14 Activated HSC predominantly express the classic p65:p50 complex but also express low levels of a p65 homodimer and high levels of a third and as yet undefined NFκB DNA binding complex. 14 Induction of NFκB during HSC activation is distinct from the classical rapid NFκB response described above and is characterised by persistent elevation of NFκB activity relative to that observed in quiescent HSC.
14 As a result, activated HSC express a variety of NFκB responsive genes that are not associated with the quiescent HSC, including interleukin 6 (IL-6) and intercellular adhesion molecule 1 (ICAM-1). [12] [13] [14] Precisely how the HSC regulates this shift towards a higher basal level of NFκB activity is not known but it is associated with a persistent reduction in the cytoplasmic and nuclear expression of IκB-α. 14 In addition, activated HSC express a hyperphosphorylated form of IκB-β that can compete with IκB-α for interaction with NFκB but lacks the inhibitory properties of IκB-α and instead maintains NFκB in a transcriptionally active state. 10 14 NFκB activity can be further elevated in a classical transient manner following stimulation of HSC with cytokines, mitogens, and CD40 ligation, which result in enhanced expression of NFκB responsive genes such as ICAM-1, cyclooxygenase 2, and interleukin 8.
11-17
"NFκB functions to promote the persistence of activated HSC and a chronic wound healing response"
The role of NFκB in the activated HSC has been studied using pharmacological inhibitors, 13 14 or more specifically by expressing a modified IκB-α protein (IκB-α A 32 A 36 ) engineered to be insensitive to the signalling pathways that serve to activate NFκB. 13 18 This latter strategy has ruled out a role for NFκB as a regulator of HSC activation (as assessed by morphology and expression of α-SMA and α1(I) collagen) and proliferation, but has demonstrated that NFκB protects HSC against tumour necrosis factor α (TNF-α) induced apoptosis. 18 This important observation suggests that NFκB functions to promote the persistence of activated HSC and a chronic wound healing response. In support of this idea, the NFκB inhibitor gliotoxin promotes accelerated recovery from carbon tetrachloride induced liver fibrosis in rats via its ability to stimulate HSC apoptosis. 19 
AP-1
AP-1 is composed of at least one Jun family protein (c-Jun, JunB, and JunD) which can either form a homodimer or heterodimerises with another Jun protein or with a member of the related Fos (c-Fos, FosB, ∆FosB, Fra1, and Fra2) family. 20 AP-1 dimers stimulate transcription by binding to a palindromic DNA sequence (TGAC/GTCA) commonly found in the promoter regions of a wide variety of genes involved in the control of cell growth, division, differentiation, and fate. 20 21 AP-1 activity is itself regulated by transcriptional and post-transcriptional control of the expression of the different fos and jun genes. [21] [22] [23] However, AP-1 function is also controlled by its interaction with stimulatory or inhibitory proteins and through post-translational modifications of which phosphorylation of the Fos and Jun components by mitogen activated protein kinase and JNK signal transducers is the most important. 23 24 Quiescent HSC lack AP-1 activity but during culture activation transiently express c-Fos, Fra1, c-Jun, and JunB which in the myofibroblast-like HSC are replaced by a persistent AP-1 activity consisting of Fra2, FosB, and JunD. 25 "As Jun proteins are essential components of AP-1 dimers, JunD will therefore play a significant role in HSC activation and fibrosis" Recent data from our laboratory have shown that JunD is functionally the most important of the constitutive AP-1 factors in activated HSC, being required for induction of tissue inhibitor of metalloproteinase 1 (TIMP-1) and IL-6 gene transcription. 26 Mutagenesis studies of the TIMP-1 and IL-6 promoters showed that JunD must coregulate expression of these fibrogenic genes with other transcription factors expressed in activated HSC. In the case of the IL-6 gene, the other critical factors are NFκB and NF-IL6 (CCAAT/enhancer binding protein β (C/EBPβ)) together with an as yet undefined heterodimeric partner for JunD. 26 By contrast, TIMP-1 gene transcription is regulated by JunD homodimers which appear to operate in concert with a 30 kDa nuclear protein that is induced in culture activated HSC and binds to a novel and essential DNA binding site in the TIMP-1 promoter called UTE-1. 27 JunD is also the predominant Jun family protein expressed in HSC isolated from the liver of carbon tetrachloride injured rats, 26 and as Jun proteins are essential components of AP-1 dimers, JunD will therefore play a significant role in HSC activation and fibrosis.
The constitutive AP-1 activity of activated HSC can be further stimulated and may also be modified in terms of expression of specific Fos and Jun factors by acetaldehyde, aldehydic end products, cytokines, and fibronectin. [28] [29] [30] Most significantly, these agents can promote expression and activation (via stimulation of mitogen activated protein kinase and JNK) of c-Jun homodimers and/or c-Jun:Fos heterodimers, which have been implicated as transcriptional regulators of the collagenase (matrix metalloproteinases (MMP)1/13) and stromelysin (MMP3) genes. [31] [32] [33] Therefore, shifts in the fine balance of the expression and activity of the different forms of AP-1 and their target MMP and TIMP genes in response to cues from the microenvironment of the activated HSC will promote the ability of the cell to remodel the hepatic ECM.
KRUPPEL-LIKE TRANSCRIPTION FACTORS
GC rich sequences and related GT or CACCC boxes are found in the regulatory regions of many profibrogenic genes expressed in activated HSC, including the α1(I) collagen, transforming growth factor (TGF)-β1 and type I and II TGF-β receptor genes. These sequences are recognition sites for the Kruppel-like transcription factor family that have the common structural feature of three Kruppel-like zinc fingers that mediate their specific DNA binding properties. This large and expanding family of transcription factors characteristically regulates expression of ubiquitously expressed or housekeeping genes but also control the transcription of tissue specific genes. 34 "Transcriptional regulators of HSC activation are in turn under the control of other transcription factors" Activated HSC express at least three members of the Kruppel-like transcription factor family, SP1, BTEB1, and KLF6 (formerly Zf9), all of which have the ability to regulate transcription of the α1(I) collagen gene. 30 35 36 SP1 DNA binding activity and protein expression are induced during HSC activation by an undefined post-transcriptional mechanism.
35
SP1 is a potent transcriptional regulator of α1(I) collagen expression and it associates with two GC rich regions (FP1 and FP2) of the α1(I) collagen gene promoter in activated HSC. 16 35 Mutagenesis of FP1 and FP2 results in greatly reduced activity of the α1(I) collagen gene promoter in HSC and overexpression of SP1 enhances promoter activity. 16 Rippe and colleagues demonstrated that NFκB is a potent repressor of α1(I) collagen gene transcription and operates via a mechanism that appears to involve formation of direct interactions with SP1. 16 Hence expression of α1(I) collagen in activated HSC may be attenuated by differential activation of SP1 and NFκB in response to cellular stimulation by growth factors and cytokines. Of relevance, the inflammatory cytokine TNF-α induces NFκB activity in activated HSC and also inhibits α1(I) collagen gene expression 16 37 BTEB1 mediates UV and acetaldehyde induced activation of α1(I) collagen gene transcription via a GC box that is distinct from the FP1 and FP2 sites and is located in a region (−1484 to −1476) that is far removed upstream of the transcription start site of the gene. 30 38 The BTEB1 gene is a target for AP-1 and induction of BTEB1 expression in acetaldehyde treated HSC is mediated via activation of JNK and elevation of AP-1 activity. 30 Hence expression of transcriptional regulators of HSC activation are in turn under the control of other transcription factors. It is expected that by unravelling these complex networks of gene regulation it will eventually be possible to identify transcription factors that act as master regulators or orchestrators of HSC activation.
One potential master regulator of HSC activation is the recently discovered Kruppel-like factor KLF6. In vivo and in vitro studies have shown that induction of KLF6 gene transcription is a very early event in HSC activation and that expression of KLF6 is a persistent feature of the fully activated myofibroblastic HSC. 36 In addition to stimulating transcription of the α1(I) collagen gene, 36 KLF6 also functions as a regulator of several key components of the fibrogenic TGF-β1 pathway. 39 40 Activated HSC not only secrete TGF-β1 but also express type I and II TGF-β receptors and the urokinase-type plasminogen activator which activates latent TGF-β1. 41 42 The genes encoding TGF-β1, its type I and II receptors, and urokinase-type plasminogen activator are all under the transcriptional control of GC box motifs that are targets for KLF6 activity 39 40 Future studies in KLF6 gene knockout mice should soon confirm a major regulatory role for this protein in hepatic fibrogenesis.
C/EBP
Members of the CCAAT/enhancer binding protein (C/EBP) family of transcription factors have also been implicated as regulators of α1(I) collagen gene expression. These proteins consist of a conserved DNA binding region and a leucine zipper dimerisation domain; the more divergent transactivation domain responsible for transcriptional activation and/or repression is found at the N terminal end of the proteins. 43 Work by the group led by Rojkind has shown that both TGF-β and acetaldehyde can increase expression of the α1(I) collagen gene in HSC by promoting the formation of H 2 O 2. 44 45 Accumulation of intracellular H 2 O 2 appears to stimulate expression of a p35 isoform of C/EBPβ and promotes the binding of this factor to a TGF-β responsive element located between nucleotides −378 to −345 in the mouse α1(I) collagen gene promoter. 44 45 Interaction of p35 C/EBPβ with this element then increases the rate of transcription of the α1(I) collagen gene. Rojkind's group went on to show that TNF-α induced downregulation of α1(I) collagen gene transcription also involves interaction of C/EBP factors with the −378 to −345 region of the promoter. 46 TNF-α stimulates binding of a p20 isoform of C/EBPβ and C/EBPδ, both of which act as repressors of α1(I) collagen gene transcription. 44 The TNF-α induced shift in C/EBPβ isoform binding to the promoter, from the p35 to the p20 isoform, is significant as the p20 C/EBPβ lacks a transactivation domain and therefore functions as a transcriptional repressor. 47 
E-bOX TRANSCRIPTION FACTORS AND c-Myb
E-box elements consist of a CANNTG (where N is any base) motif and bind members of the basic helix-loop-helix (bHLH) transcription factor family. 48 bHLH proteins can be broadly placed into two categories: class A factors that are expressed in a ubiquitous pattern and class B factors that are expressed in a tissue restricted manner. bHLH factors function as dimers that can include combinations of both class A and class B proteins; this creates a diverse range of transcription factors that are involved in regulating cell growth and differentiation pathways.
49-51
"It is important to determine the role played by MyoD as a transcriptional regulator of the myogenic properties of HSC"
The myogenic transcription factor MyoD is a class B bHLH protein that has a highly restricted pattern of expression limited to cells of the skeletal muscle lineage, myoid cells of the thymus, and myofibroblasts. 52 MyoD functions in cooperation with its related myogenic transcription factors Myf5, myogenin, MRF4, and the MEF2 group to regulate skeletal muscle cell determination and differentiation. 49 The recent observation that MyoD is also expressed by activated human and rat HSC in a biologically active form indicates that it may also regulate the myogenic and contractile properties of the myofibroblast-like HSC. [52] [53] [54] Although activated HSC are often referred to as being smooth muscle myofibroblast-like on the basis of their expression of α-SMA, they additionally acquire expression of the contractile IIa, IId, and perinatal skeletal muscle myosin heavy chain isoforms. 52 53 As the contractile nature of the activated HSC contributes to portal hypertension, an important pathological feature of the cirrhotic liver, 55 it is important to determine the role played by MyoD as a transcriptional regulator of the myogenic properties of HSC. As forced expression of MyoD can trigger the terminal differentiation of fibroblasts into skeletal muscle cells, 56 it will also be of great interest to determine how activated HSC can exist in a state in which they exhibit phenotypic features of both fibroblasts and muscle cells.
E-box factors have been implicated as transcriptional regulators of the mannose 6-phosphate/insulin-like growth factor II (M6P/IGFIIR) gene, which has been postulated to play a key role in fibrogenesis by binding latent TGF-β at the cell surface, thereby promoting its activation. 57 58 Weiner et al have described three functional E-box elements in the M6P/IGFIIR gene. Two of these elements are located proximal to the transcription start site and bind a novel 75 kDa (P75) nuclear protein that is downregulated in activated HSC. 57 As mutations of these proximal E-box elements enhance promoter activity, it is thought that P75 is a repressor of transcription. The third E-box is located distal to the transcription start site, is essential for M6P/ IGFIIR promoter activity, and displays enhanced protein binding in HSC treated with platelet derived growth factor BB. 58 The as yet uncharacterised factor binding to this distal E-box is distinct from the P75 repressor. These data suggest that activation of latent TGF-β, a key step in fibrogenesis, is influenced by the activity of repressor and activator bHLH factors.
A major myogenic feature of activated HSC is their abundant expression of α-SMA; until recently there was little information available regarding the control of α-SMA gene transcription in HSC. However, Buck et al have now demonstrated that a region of 271 base pairs located immediately upstream of the transcription start site of the rat α-SMA gene is sufficient to direct transcription in activated rat HSC. 59 This region contains two E-boxes of which the E-box located proximal to the start site of transcription has previously been implicated as a binding site for the transcription factors c-Myb and NFκB, both of which are induced during HSC activation.
11 c-Myb is the prototype of a family of related Myb proteins that act as either positive or negative transcriptional regulators of a wide variety of genes. 60 Buck et al showed that c-Myb binds to an E-box-like sequence that is located immediately adjacent to the proximal E-box. 59 The most exciting aspect of this study was the demonstration that c-Myb not only stimulates the activity of a transfected α-SMA promoter but is also required for expression of the endogenous α-SMA gene. Perhaps even more remarkable was the finding that disruption of c-Myb expression using antisense oligonucleotides resulted in a blockade of HSC activation, as judged by morphological criteria. Further studies on c-Myb function in the activated HSC, including confirmation of an in vivo role in HSC activation and fibrosis, are now required. But this study exemplifies how an understanding of the transcriptional regulation of HSC activation may identify potential therapeutic targets.
PPARγ AND TRANSCRIPTION FACTOR ACTIVITIES ASSOCIATED WITH THE QUIESCENT HSC
The transcription factors discussed so far have the common feature of being associated with the activated phenotype of HSC. It is however also important to study the function of transcription factors that are active in quiescent HSC, especially if these activities are diminished during HSC activation. These latter types of transcription factors may function as inhibitors of HSC activation, as suggested by a series of recent papers describing the peroxisome proliferator activated receptor γ (PPARγ) as a novel modulator of HSC biology. [61] [62] [63] PPARγ is a member of the steroid/thyroid hormone nuclear receptor superfamily that is implicated in metabolic diseases such as diabetes and operates as an obligate heterodimer with the retinoid X receptor to regulate gene transcription and cellular differentiation. 64 65 Expression of PPARγ protein is dramatically reduced in HSC activated both in vitro (human and rat cells) and in vivo (rat cells isolated from bile duct ligated rats). [61] [62] [63] These studies also showed that HSC activation is associated with significantly reduced activity of transfected synthetic promoters that contain multiple copies of the PPAR response element. 62 63 "There may be genuine promise in the clinical use of PPARγ ligands for the treatment of hepatic fibrosis and cirrhosis"
A variety of PPARγ agonists and antagonists are available that act as ligands for the nuclear receptor and either promote or inhibit its transcriptional activity. 65 The PPARγ agonist 15-deoxy ∆ 12,14 -prostaglandin J 2 was shown in all three of the reported studies to block multiple phenotypic features of the activated HSC including platelet derived growth factor induced proliferation, DNA synthesis, chemotaxis, and expression of α-SMA, α1(I) collagen, and monocyte chemotactic protein 1. [61] [62] [63] Impressively, these effects were reproduced when exposing activated HSC to a variety of different PPARγ agonists and were abrogated in HSC treated with a PPARγ antagonist. If these exciting observations can be reproduced in animal models of hepatic fibrosis then there may be genuine promise in the clinical use of PPARγ ligands for the treatment of hepatic fibrosis and cirrhosis.
Reports of other transcription factors that undergo diminution of their expression or activity as HSC activate are rare but two such factors have been identified that belong to the bHLH family. One is the P75 repressor of M6P/IGFIIR gene transcription and the other is Id1. 54 Quiescent HSC express abundant levels of Id1 mRNA that are rapidly and persistently diminished on culture induced activation. Id1 is a bHLH factor that lacks a DNA binding domain but can form transcriptionally inactive dimers with other bHLH transcription factors. 66 When Id1 is forcibly overexpressed it will block the terminal differentiation of muscle and nerve cells by preventing the function of myogenic and neurogenic bHLH proteins. As induction of MyoD DNA binding activity coincides with loss of Id1 expression in HSC, it is plausible that Id1 acts to inhibit the activity of MyoD in quiescent HSC. 54 Finally, Bahr and colleagues 25 and Knittel and colleagues 67 have also identified Ets-1, a member of the Ets transcription factor family that regulates expression of many genes involved in ECM synthesis and turnover, including TIMP-1, 25 68 as a factor that undergoes downregulation of its expression during HSC activation. The functional significance of P75, Id1, and Ets-1 as regulators of the HSC phenotype should now be determined using viral or plasmid based gene transfer systems to generate forced overexpression of these factors in the activated HSC.
SUMMARY AND DIRECTIONS FOR FUTURE RESEARCH
The complexity of events at the level of gene transcription associated with HSC activation appears daunting at first. In particular, the requirement for the coordinated activity of several transcription factors to control expression of any one fibrogenic protein such as α1(I) collagen (SP1, KLF6, BTEB, AP-1, NFκB, C/EBP, PPARγ) may seem discouraging. However, by identifying transcription factors such as JunD, KLF-6, c-Myb, and PPARγ that are individually able to contribute to the transcriptional regulation of multiple phenotypic characteristics of the activated HSC, it will eventually be possible to map the major transcriptional pathways that result in HSC activation and thereby promote fibrosis. Future efforts should be particularly directed to in vivo studies with gene deleted mice or virus vector mediated delivery of dominant negative inhibitors to confirm a pathophysiological role for these potential orchestrators of HSC activation in the fibrogenic process. There should also be attention placed on the regulation of gene transcription at the level of the chromatin structure which, through the tightly regulated activity of the histone acetyl transferases and the histone deacetylases, can exert global control over gene expression. 4 6 69 The findings of these future studies will provide mechanisms for the experimental manipulation of the HSC phenotype and are likely to lead to the discovery and development of new therapies in the treatment of hepatic fibrosis.
